Gene-editing by CRISPR–Cas9 in combination with anthracycline therapy <i>via</i> tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppressionChen-Shen Wang, Yu‐Li Lo|Nanoscale Horizons|2021Cited by 57